Are multi-strain products better than single-strain probiotic products?

Multi-strain products containing several strains in high doses do not necessarily have a better effect than a single-strain product. Important criteria when choosing a probiotic product are:

• The probiotic bacteria must be defined on strain level

• The probiotic product must have been tested in human clinical studies, with the same dose and with the same bacterial strain(s) as in the commercial product.

What is Lactobacillus reuteri?

Lactobacillus reuteri (L. reuteri) is a probiotic bacteria that has co-evolved with humans since the beginning of time, and because of that it is adapted to its host. L. reuteri is among the first bacterial species to naturally become established in the microbiota of the newborn. BioGaia probiotic products with L. reuteri are among the most scientifically well-documented probiotics in the world with regard to both efficacy and safety. To date 202 clinical studies with BioGaia’s L. reuteri-strains have been performed in more than 17,200 people of all ages. Positive results have been shown for several gastrointestinal disorders and oral health. Results have been published in 180 articles in scientific journals (February 2019).

Read more about Lactobacillus reuteri.

What are probiotics?

Probiotics are good bacteria that can be found in dietary supplements and sometimes in dairy products. Probiotics are defined as ”live microorganisms that, when administered in adequate amounts, confer a health benefit on the host.” (WHO/FAO 2002, Hill C et al. 2014). An important criterium for qualifying as a true probiotic is that health benefits have been proven in clinical studies. Furthermore, a probiotic product must contain the same bacterial strain(s) and the same dose that was used in the clinical studies.

 

Where can I buy your products?

Our products are sold by distribution partners in around 100 countries. Usually, they are sold through the major pharmacy chains. For information on where to buy our products, please contact our distribution partner in your country.

Lactobacillus reuteri in the treatment of Helicobacter pylori in Sardinian patients

Open study to investigate if the eradication rate of H. pylori in adults is improved by L. reuteri DSM 17938, as an adjunct during 10-day eradication therapy and for 10 days thereafter. Forty-five (45) patients were included.

The rate of eradication was 93.3% (42/45). In 2/4 (50%) previously treated for H. pylori the infection was also eradicated.

Side effects were reported in 8 subjects: mild diarrhoea for a few days (n=5), and abdominal discomfort (n=3).

Conclusion

Proton pump inhibitor-tetracycline-metronidazole-L. reuteri therapy provided high eradication rates with few side effects, and excellent compliance.

BioGaia Gastrus

BioGaia Gastrus is a food supplement containing the patented lactic acid bacterium Lactobacillus reuteri Gastrus (L. reuteri DSM 17938 and L. reuteri ATCC PTA 6475). Because both strains in L. reuteri Gastrus naturally colonize humans they have a strong adaptation to persist and interact with humans. BioGaia Gastrus has been tested in clinical trials and proven effective and safe.